Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

CMS Plans Three-Step Medicare Rx Education Campaign

This article was originally published in The Pink Sheet Daily

Executive Summary

The focus of the 18-month Medicare Part D benefit education campaign will be on beneficiary awareness, decisionmaking and urgency. The effort will be aided by HHS agencies, members of Congress and other Cabinet departments.

You may also be interested in...



Image Problems Could Relegate Industry To Supporting Role In Medicare PR

The responsibility for a Medicare drug benefit public relations campaign falls on CMS' shoulders, Schering-Plough VP Atkins says. Rx industry can play a supporting role but "I'm not sure beneficiaries are inclined to take our word for it," exec says. PhRMA is expected to launch its own nationwide PR image campaign in the second quarter.

Italy Leads European Push Into Conditional Reimbursement

Italy claims to have pushed farther into managed entry agreements than other European countries with strong clawback provisions on new drugs – particularly cancer drugs – if they don't work as well as their manufacturers claim. The financial clawbacks are supported by extensive outcome data collection across the country's twenty regions.

Changes To The NHS: How Can Pharma Best Position Itself?

The U.K.’s Health and Social Care Bill was introduced into Parliament on Jan. 19, offering a new commercial landscape best navigated by pharma through bolstered relationships with general practitioners.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS061912

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel